Lynelle Hoch is President, Cell Therapy Organization, leading Bristol Myers Squibb’s cross-functional cell therapy business since June 2021. She oversees the teams responsible for research, development, manufacturing and commercialization of BMS’ marketed and pipeline cell therapies, united in the mission of unlocking cell therapy’s full potential and putting patients on the path to a cure. “Cell therapy represents one of the most promising and exciting scientific advancements that will continue to revolutionize the way we approach cancer treatment, and now potentially B-cell mediated autoimmune disorders,” says Lynelle. “At BMS, transforming patients’ lives through science motivates our talented teams to do the hard work to further this potential, and we’re only just beginning.”
Since starting her career as an engineer intern in manufacturing, Lynelle has held increasingly senior positions at BMS over the last 25+ years in sales, marketing and market access, both internationally and in the U.S. Prior to cell therapy, she was general manager for BMS in the UK and Ireland, and before that led marketing for the immuno-oncology portfolio. Lynelle became executive sponsor of the BMS Network of Women (B-NOW) in January 2025. Externally, she’s been named a Top 50 Health Influencer by MM&M/PRWeek, one of Fierce Pharma’s 2023 Fiercest Women in Life Sciences.
